BINDING STUDIES OF EPIDERMAL GROWTH FACTOR RECEPTOR TARGETED COMPOUNDS USING SURFACE PLASMON RESONANCE by Kankanala, Spandana
Virginia Commonwealth University
VCU Scholars Compass
Theses and Dissertations Graduate School
2009
BINDING STUDIES OF EPIDERMAL
GROWTH FACTOR RECEPTOR TARGETED
COMPOUNDS USING SURFACE PLASMON
RESONANCE
Spandana Kankanala
Virginia Commonwealth University
Follow this and additional works at: http://scholarscompass.vcu.edu/etd
Part of the Chemical Engineering Commons
© The Author
This Thesis is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in Theses
and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact libcompass@vcu.edu.
Downloaded from
http://scholarscompass.vcu.edu/etd/1737
Virginia Commonwealth University  
 
This is to certify that the thesis prepared by Spandana Kankanala entitled BINDING 
STUDIES OF EPIDERMAL GROWTH FACTOR RECEPTOR TARGETED 
COMPOUNDS USING SURFACE PLASMON RESONANCE has been approved by his 
or her committee as satisfactory completion of the thesis requirement for the degree of  
Masters 
 
 
Michael H. Peters, Virginia Commonwealth University  
 
Stephen S. Fong, Virginia Commonwealth University 
 
Hu Yang, Virginia Commonwealth University 
 
Frank Gupton, Virginia Commonwealth University 
 
Russell D. Jamison, Virginia Commonwealth University 
 
Dr. F. Douglas Boudinot, Dean of the Graduate School 
 
 
[Click here and type the Month, Day and Year this page was signed.] 
 
© Spandana Kankanala 2009 
All Rights Reserved 
 
BINDING STUDIES OF EPIDERMAL GROWTH FACTOR RECEPTOR TARGETED 
COMPOUNDS USING SURFACE PLASMON RESONANCE 
A Thesis submitted in partial fulfillment of the requirements for the degree of Masters at 
Virginia Commonwealth University. 
 
By 
 
SPANDANA KANKANALA 
B Tech, Gokaraju Rangaraju Institute of Engineering and Technology, India, 2006 
 
 
Director: MICHAEL H. PETERS 
PROFESSOR, CHEMICAL AND LIFE SCIENCES ENGINEERING 
 
 
Virginia Commonwealth University 
Richmond, Virginia 
May, 2009 
   
 ii 
Acknowledgements 
My Family is my strength. It’s their never ending love and support which helped 
me be what I am today. I would like to thank my parents Mr. Narayana Kankanala 
and Mrs. Vasumathi Devi Popuri for always understanding my needs and 
encouraging me to fulfill my interests and my brother Dheeraj Kankanala who has 
always looked out for me.  
 
I would like to express my gratitude to my adviser and mentor Dr. Michael H. 
Peters for having immense faith in me throughout my research which encouraged 
me to do my best. He has always been very supportive and friendly. I thank him 
for all the financial and moral support he has given me which made my work lot 
easier. I also thank him for creating such a tension free work environment. I thank 
Dr. Stephan S. Fong and Dr. Hu Yang for being in my committee and sharing 
their expertise and giving helpful feedback.  
 
I would like to thank Dr. Kenneth J. Wynne who is like my family away from 
family. He has been an inspiration to me in many ways. I would like to convey 
special thanks to Dr. Matthew C T Hartman and his research group for all the help 
with my work. I appreciate the time he spent teaching me and it was a great 
learning experience working with him.  
 
I would like to thank my best friend and well wisher Chandra Parvathaneni 
without whom my stay here wouldn’t have been so easy and comfortable. I would 
like to extend special thanks to my dear friend Supriya Mocherla in whom I found 
a friend, philosopher and guide. I would also like to thank my close friends 
Vanaja Devarapalli, Swetha Jilla and Mogulapalli Narsingam who have been 
there for me and helped me through tough times.  
 
I would like to thank my roommate and dear friend Harsha Battapady and all my 
friends Devnath Vasudevan, Shanthi Kanchibhotla, Hema Shanthi Aluri, 
Lopamudra Das and Tejas Desai for being so supportive and caring. I thank my 
colleagues and lab mates Laxmi Mullapudi, Ashima Chakravorty, Sundar 
Gadepalli and all my friends for keeping a great company. 
 
  
  iii 
Table of Contents 
Page 
Acknowledgements .........................................................................................................ii 
List of Tables ...............................................................................................................vii 
List of Figures ..............................................................................................................viii 
Chapter  
 1.    Introduction ................................................................................................ 13 
1.1  Overview ......................................................................................... 13 
                 1.2  Objective.  …………………………………………………………..14 
  2. Theory ......................................................................................................... 16 
2.1  EGF Pathway: Cell growth and proliferation..................................... 16 
2.2  Cancer Research: Antibodies ............................................................ 18 
2.3  Binding studies: EGF/Cetuximab with EGF Receptor……………….20 
  3. Literature Review ........................................................................................ 22 
3.1  Overview of the Chapter ................................................................... 22 
3.2  Review of previous studies on binding of EGF to heterogeneous EGFR
.......................................................................................................... 22 
3.3  Review of previous studies on cetuximab binding to EGFR………...25 
3.4  Considerations for Biacore experiments……………………………..26 
      3.4.1  Mass Transport………………………………………………...26    
      3.4.2  Analyte Concentrations ……………………………………….27 
   
 iv 
              4.   Experimental Background…………………………………………………..29 
                      4.1  Surface Plasmon Resonanace…………………………………………29 
                            4.1.1  Principle of SPR…………………………………………….......29 
                      4.2  Instrumentation ……………………………………………………....31 
                            4.2.1  Optical System………………………………………………….32 
                            4.2.2  Liquid handling System………………………………………...33 
                            4.2.3  Sensor Chip…………………………………………………….33 
                      4.3  Immobilization……………………………………………………….34 
                            4.3.1  Covalent Immobilization……………………………………….34 
                            4.3.2  Capturing methods……………………………………………..35 
                      4.4  Amine Coupling……………………………………………………...36 
                      4.5  Kinetics……………………………………………………………….37 
                      4.6  Regeneration Scouting………………………………………………..38             
   5. Materials and Methods………………………………………………………39 
                      5.1  Materials……………………………………………………………...39 
                            5.1.1  Antibodies……………………………………………………...39 
                            5.1.2  Buffers and Stock solutions for Biacore………………………..39 
                            5.1.3  Reagents and Stock solutions for peptide synthesis……………40 
                      5.2  Equipment……………………………………………………………41 
                            5.2.1  Biacore 3000……………………………………………………41 
                            5.2.2  CEM Microwave Peptide Synthesizer………………………….42 
                            5.2.3  Other Instruments………………………………………………42 
   
 v 
                      5.3  Peptide Synthesis…………………………………………………......42 
                            5.3.1  Synthesis of P-13…………………………………………….....43 
                            5.3.2  Washing and Cleaving the Peptide……………………………..43 
                            5.3.3  Purification of peptide……………………………………….....44 
                            5.3.4  Concentration of peptide……………………………………......44   
                      5.4  BIACORE: Surface Preparation………………………………………45    
                            5.4.1  Preparation of sEGFR as ligand………………………………...45 
                            5.4.2  Immobilizing sEGFR on CM5………………………………….46 
                      5.5  BIACORE: Kinetic Analysis of protein-protein or peptide-protein 
                                                 interactions……………………………………………….47    
                            5.5.1  EGF Interaction………………………………………………….47 
                            5.5.2  Cetuximab Interaction……………………………………….......48 
                            5.5.3  Peptide Interaction………………………………………………48  
   6. Results and Discussion……………………………………………………….50 
6.1  Synthesis of P-13…………………………………………………… .50 
      6.1.1  Calculating the mass of P-13…………………………………...50 
                            6.1.2  Determining P-13 mass using MALDI Mass Spec…………….50 
      6.1.3  Purification of P-13…………………………………………….52 
                       6.2  Immobilization of sEGFR on CM5 sensor chip……………………...53 
6.3  Kinetic Analysis……………………………………………………...54 
      6.3.1  Binding studies with EGF………………………………………55 
      6.3.2  Binding studies with Cetuximab………………………………..59 
   
 vi 
      6.3.3  Binding studies with P-13………………………………………61 
6.4  Discussion……………………………………………………………62 
   7.  Future Work................................................................................................ 66 
Literature Cited ............................................................................................................. 67 
 
   
 vii 
List of Tables 
Page 
Table 2.2-1: Monoclonal antibodies to treat cancer........................................................ 19 
Table 3.2-1: Experimental systems used for EGF/EGFR interaction. ............................. 24 
Table 5.1-1: Buffers and Stock solutions for Biacore. .................................................... 40 
Table 5.1-2: Reagents and Stock solutions for peptide synthesis. ................................... 40 
Table 5.1-3: Reagents and buffers used for protein purification (HPLC)........................ 41 
Table 5.1-4: Solutions used for MALDI Mass Spec....................................................... 41 
Table 6.3-1: Summary table for equilibrium binding constants for EGF/sEGFR interaction.
...................................................................................................................................... 59 
Table 6.3-2: Summary table for equilibrium binding constants for Cetuximab/sEGFR 
interaction. .................................................................................................................... 61 
 
   
 viii 
List of Figures 
Page 
Figure 2.1-1: EGF receptor signal transduction pathway................................................ 17 
Figure 2.3-1: Model for EGF induced activation of EGFR............................................. 20 
Figure 2.3-2: Model for Cetuximab preventing EGF binding to EGFR ......................... 21 
Figure 2.3-3: Structure of P-13 binding to EGFR-ED .................................................... 21 
Figure 4.1-1: Demonstration of Surface Plasmon Resonance. ........................................ 30 
Figure 4.1-2: Sensogram ............................................................................................... 31 
Figure 4.2-1: Three corner stones of Biacore technology ............................................... 32 
Figure 4.4-1: Illustrative graph of Amine coupling ........................................................ 37 
Figure 6.1-1: Data from Mass Spec for purified P-13..................................................... 51 
Figure 6.1-2: Data from Mass Spec for purified P-13 after solvent evaporation ............. 52 
Figure 6.1-3: Chromatogram obtained from purification of P-13 using HPLC ............... 53 
Figure 6.2-1: Immobilization of sEGFR using amine coupling ...................................... 54 
Figure 6.3-1a: Kinetic analysis of EGF with sEGFR...................................................... 55 
Figure 6.3-1b: Kinetic analysis of EGF with sEGFR...................................................... 56 
Figure 6.3-2: Scatchard plot of EGF binding to sEGFR ................................................. 56 
Figure 6.3-3: Data from Mass transfer control experiment............................................. 58 
Figure 6.3-4: Kinetic analysis of C225 with sEGFR ...................................................... 60 
Figure 6.3-5: Kinetic analysis of P-13 with sEGFR ....................................................... 62 
 
   
 ix 
ABBREVIATIONS 
 
 
CHCA                                               α-Cyano-4-hydroxy-cinnamic acid 
DCM                                                 Dichloromethane 
DFM                                                  N, N-Dimethylformamide 
DIEA                                                 N, N-Diisopropylethylamine 
DODT                                               3, 6-Dioxa-1, 8-octane-dithiol 
EGF                                                   Epidermal Growth Factor 
EGFR                                                Epidermal Growth Factor Receptor 
EDC                                                  1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
                                                          Hydrochloride 
EDTA                                               Ethylenediaminotetraacetic acid 
HBS-EP                                            HEPES-buffered saline containing EDTA and 
                                                          surfactant P-20. 
HBTU                                               O-Benzotriazole-N,N,N’,N’-tetramethyl-uronium- 
                                                          hexafluoro-phosphate 
HEPES                                              N-2-Hydroxyethylpiperazine-N’-2-ethanesulfonic 
HOBt                                                 1-Hydroxybenzotriazole 
HPLC                                                High Performance Liquid Chromatography 
Fab                                                    Fragment, antigen-binding 
IFC                                                    Integrated fluidic cartridge 
IgG1                                                  Immunoglobulin G1 
   
 x 
ka                                                                                  Association rate constant (M-1s-1) 
kd                                                                                  Dissociation rate constant (s-1) 
KD                                                     Equilibrium dissociation constant (M) 
MAb                                                  Monoclonal Antibody 
MALDI-TOF                                    Matrix-assisted laser desorption ionization-time-of 
                                                          -flight        
MeCN                                               Acetonitrile 
MWA                                                                         Molecular weight of analyte 
MWL                                                                         Molecular weight of ligand 
NHS                                                  N-hydroxysuccinimide 
NMP                                                 1-Methyl-2-Pyrrolidone 
Req                                                                               Response at equilibrium 
RL                                                                                Ligand immobilization level in RU 
Rmax                                                                            Maximum analyte binding capacity in RU 
RU                                                     Response Units 
sEGFR                                               soluble EGFR 
SPR                                                   Surface Plasmon Resonance 
Sm                                                     Stoichiometry 
TFA                                                   Trifluoroacetic acid 
TGF                                                   Transforming Growth Factor 
TIS                                                    Triisopropylsilane 
UV-Vis                                              Ultraviolet – visible spectroscopy 
   
 xi 
 
 
 
 
Abstract 
 
 
 
BINDING STUDIES OF EPIDERMAL GROWTH FACTOR RECEPTOR TARGETED 
COMPOUNDS USING SURFACE PLASMON RESONANCE 
By Spandana Kankanala, B Tech 
A Thesis submitted in partial fulfillment of the requirements for the degree of Masters at 
Virginia Commonwealth University. 
 
Virginia Commonwealth University, 2009 
 
Major Director:  Michael H. Peters 
Professor, Chemical and Life Sciences Engineering 
 
 
 
   
 xii 
The study of binding kinetics of proteins plays an important role in understanding 
molecular mechanisms that drive biological processes. The binding rate constants reflect 
the dynamics of the system and associated biological activity measurements of the 
association and dissociation rate constants make it possible to compare different 
interactions in a standardized manner and help elucidate a mechanistic understanding of 
binding events.  
In our study, we used Surface Plasmon Resonance (SPR) technology (Biacore) to 
study the binding kinetics of the antibodies EGF, Cetuximab and a candidate drug P-13 
with the receptor EGFR. The candidate drug P-13 was synthesized and tested on Biacore 
for binding kinetics. This peptide is anticipated to bind to domain III of EGFR-ED. The 
study also compared the interaction kinetics of EGF/EGFR and Cetuximab/EGFR with the 
previous literature and a summary of results is produced. 
Our Biacore experiments on EGF/sEGFR suggest a two-state affinity binding with 
90% high affinity binding sites, which compares with the previous studies in cells. The 
dissociation rate constant for Cetuximab/sEGFR interaction was reported for the first time 
using SPR while the other kinetic constants were comparable to literature. Although the 
peptide P-13 demonstrated a relatively weak (micro molar) binding capacity to the 
receptor, as compared with EGF and Cetuximab, the dissociation rate constant was 
comparable to a nano molar binder. Hence, we argue that the region of binding of P-13 is 
sterically inhibited as per the receptor orientation, which is consistent with the computer 
design data supplied with this candidate drug.     
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CHAPTER 1  Introduction 
 
1.1   Overview 
 
        Cancer is one of the major causes of death in the U.S. It starts as the cell begins to 
divide uncontrollably. This cell multiplication eventually leads to a visible mass called a 
tumor. Tumor start as benign, which are not fatal, but sometimes change into malignant 
tumors as characterized by spreading (metastasis) to multiple regions of the body. The type 
of the cancer is identified by the initial tumor location. There are more than 100 types of 
cancer, including breast cancer, skin cancer, lung cancer, colon cancer, prostate cancer, and 
lymphoma (Jemal et al., 2008). 
        Colorectal cancer is the third most common cancer found in U.S. The American 
Cancer Society estimates that there will be about 108,700 new cases of colon cancer and 
40,740 new cases of rectal cancer in 2008. Combined, this might cause 49,960 deaths in 
U.S alone. Colorectal cancer, cancer that starts either in the colon or the rectum, is treated 
by surgery, radiation therapy, chemotherapy or targeted therapies called monoclonal 
antibodies. 
        Although surgery, radiation therapy, and chemotherapy are suggested treatments for 
cancer, there are common side effects including bleeding from surgery, damage to nearby 
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organs during operation, mild skin irritation due to radiations, nausea, diarrhea, rectal and 
bladder irritation, tiredness. While chemotherapy kills cancer cells, it also damages some 
normal cells which cause side effects like increased chance of infection, hair loss, easy 
bleeding or bruising after minor cuts or injuries. 
        Targeted therapies (monoclonal antibodies) are used to destroy some types of cancer 
cells while causing little harm to normal cells. They are designed to recognize certain 
proteins (receptors) that are found on the surface of particular cancer cells. The major 
criteria for the proteins to be targets for treatment are that they should be accessible to the 
antibodies and be available during the whole treatment time. In this thesis, we concentrate 
on EGFR (Epidermal Growth Factor Receptor), the target receptor, whose constitutive 
activity leads to cell proliferation and, in turn, cancer. EGFR is highly upregulated in 
colorectal cancers and, thus, has received significant attention as a target for drug 
development.  
 
1.2   Objective 
 
        In this thesis, the binding kinetics of the drug Cetuximab (monoclonal antibody) and 
the growth factor EGF (Epidermal Growth Factor) with sEGFR (soluble EGFR) were 
studied using SPR (Surface Plasmon Resonance). The kinetic rate constants and the 
methods used to obtain values for EGF and Cetuximab (C225) interactions with sEGFR 
are compared to that in the literature. Our goal is to carry on SPR studies in an 
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arrangement which would imitate the natural system as closely as possible in order to 
obtain kinetic constants consistent with cellular-based results.  
 
        A thirteen residue peptide, code named P-13, has been proposed as an EGFR inhibitor 
that binds to residues near 500 of domain III (Peters, 2009). One of the goals of this 
research is to test P-13 in Biacore and compare its binding to that of EGF and Cetuximab.  
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CHAPTER 2  Theory 
 
2.1  EGF Pathway: Cell growth and proliferation 
 
        The epidermal growth factor receptor (EGFR) family, also called ErbB family, 
consists of four kinds of receptors, EGFR (ErbB1), Neu (ErbB2), ErbB3, and ErbB4. Each 
receptor consists of a cytoplasmic tyrosine kinase domain, a single transmembrane 
spanning region, and an extracellular region, the latter of which contains approximately 
620 amino acids. The extracellular region of each receptor has four domains, L1 and L2 (or 
I and III), which are luecine-rich regions and CR1 and CR2 (or II and IV), which are 
cystine-rich (Ferguson et al., 2003). The ligand EGF binds to the extracellular domain of 
the receptor and aids in the dimerization of the receptors to activate the signal cascade for 
gene transcription and cell proliferation.  
        The EGF receptor has many growth factors, such as Epidermal Growth Factor (EGF) 
and Transforming Growth Factor-α (TGF-α). EGF when bound to the extracellular domain 
of EGFR leads to receptor dimerization and activation of tyrosine kinase enzyme located in 
the intracellular domain of the receptor. Kinase activation leads to transphosphorylation of 
the receptor intracellular domains and initiates multiple signal transduction pathways that 
eventually result in the signal reaching the nucleus.  
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Figure 2.1-1  EGF receptor signal transduction pathway 
 
        The Ras-Raf-MEK-MAPK pathway is activated through the growth factor receptor 
bound protein 2 (GRB2)-SOS complex. The receptor mediated signaling also activates 
phosphotidylinositol 3-kinase (PI3K)-AKT pathway, which contributes to anti-apoptic 
effects of EGFR activation. Additionally, transcription activator (Stat) proteins are also 
activated. These EGFR downstream signaling pathways lead in cellular responses like cell 
proliferation, differentiation, cell motility, adhesion and angiogenesis. The over 
expression, mutation or truncation of the EGF receptor leads to constant activity of the 
receptor and hence leads to excess cell growth and, in turn, cancer. EGFR is implicated in 
   
 18 
the development of wide range of epithelial cancers, including those of breast, colon, head 
and neck, kidney, lung, pancreas and prostate (Scaltriti et al., 2006). 
 
2.2  Cancer Research: Antibodies 
 
        Recent research has explored promising methods to suppress tumor growth in tissues. 
Over the last decade, targeted therapies have been proven to be an effective way to inhibit 
tumors with fewer severe adverse events in cancer intervention since they specifically 
interfere with signaling pathways essential for tumor growth. Monoclonal antibodies and 
protein tyrosine kinase inhibitors are two classes among these new therapeutic 
interventions.   
        The monoclonal antibodies target the extracellular ligand binding domain of the 
receptor and prevent the activation of the receptor by its respective growth factor. On the 
other hand, tyrosine kinase inhibitors are small molecules which mainly target the ATP 
binding domains of the receptor and thereby prevent phosphorylation of the kinase domain 
and its activation.  
        One simple and effective way to treat tumors is the use of monoclonal antibodies 
along with other cancer therapies or individually. Monoclonal antibodies are produced by 
forming a hybrid cell that has the ability to produce the desired antibody continuously. In 
this technology, the tumor cells that can replicate endlessly are fused with mammalian 
cells that produce the antibody. This results in “hybridoma”, the fused cell, which 
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continually produces the antibody. The antibodies thus produced are pure as they come 
from only one type of cell (Schwaber, J et al., 1973).   
        Monoclonal antibodies function in cancer treatment through various mechanisms. 
They can directly affect the tumor by causing apoptosis or programmed cell death. They 
can compete with growth factors in binding to receptor domains and thereby arrest 
signaling for cell proliferation. These antibodies can be also used in the clinic as 
conjugated antibodies, with a radionuclide or chemotherapy agent attached or as non-
conjugated antibodies, without any toxins or radionuclide attached to them. 
        The FDA (Food and Drug Administration) approved the first monoclonal antibody for 
cancer treatment in 1997. Today several of these drugs are in market for treating certain 
cancers. Below is the table of the MAbs approved by the FDA for cancer treatment. 
 
Table 2.2-1  Monoclonal antibodies used to treat cancer (Rang, H.P. et al., 2003)  
MAb Name Trade 
Name 
Used to Treat Approved 
in: 
Rituximab Rituxan Non-Hodgkin lymphoma 1997 
Trastuzumab Herceptin Breast Cancer 1998 
Gemtuzumab ozogamicin Mylotarg Acute myelogenous leukemia 
(AML) 
2000 
Alemtuzumab Campath Chronic lymphocytic leukemia 
(CLL) 
2001 
Ibritumomab tiuxetan Zevalin Non-Hodgkin lymphoma  2002 
Tositumomab Bexxar Non-Hodgkin lymphoma 2003 
Cetuximab Erbitux Colorectal cancer 
Head & neck cancers 
2004 
2006 
Bevacizumab Avastin Colorectal cancer 
Non-small cell lung cancer 
Advanced breast cancer 
2004 
2006 
2008 
Panitumumab Vectibix Colorectal cancer 2006 
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        Cetuximab (Erbitux) is an antibody against EGFR protein as it blocks the activation 
of this receptor. It was approved by FDA in 2004 for treatment of colorectal cancer. 
Recently, it was approved for the treatment of head and neck cancers (2006).  
 
2.3  Binding studies: EGF/Cetuximab/P-13 with EGF Receptor 
 
        Structural studies on EGF-EGFR complex have shown that the growth factor binds to 
the domains I and III of extracellular-EGFR simultaneously. The unliganded EGF receptor 
is in its unextended form (inactive state) with domain II buried by an intramolecular 
interaction with domain IV. When the growth factor binds to the receptor (domains I and 
III), it alters the spatial arrangement of the domains and this domain rearrangement 
exposes a critical region, known as the dimerization arm, of domain II. This aids in the 
dimerization of the receptor and thus activation of cell signaling (Li et al., 2005).  
 
                     
                           
Figure 2.3-1  Model for EGF induced activation of EGFR 
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        Cetuximab, as shown in structural studies, binds exclusively to domain III of the EGF 
receptor that overlaps the EGF binding site. Thus, it prevents the EGF from binding to the 
receptor and thereby prevent tumor causing cell signaling (Li et al., 2005).  
 
                         
C Ligand
C C
E
E
A. Tethered monomers B. Cetuximab bound
to domain -III 
C. EGF cannot
induce dimerization .  
Figure 2.3-2  Model for Cetuximab preventing EGF binding to EGFR 
 
        P-13 is a thirteen residue peptide which is anticipated to bind domain III of EGFR 
extracellular region. The peptide binds to residues near 500 of domain III (Peters, 2009) 
and Figure 2.3-3 shows the binding regions of peptide on sEGFR.    
 
 
Figure 2.3-3  Structure of P-13 binding to EGFR-ED 
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CHAPTER 3  Literature Review 
 
3.1  Overview of the Chapter 
 
        In this chapter, we review previously published studies on the binding of antibodies 
EGF and Cetuximab to EGFR. We compare studies carried over in cells with that on 
Biacore. In the later part of this chapter, important Biacore phenomena are discussed. 
 
3.2  Review of Previous Studies on Binding of EGF to Heterogeneous EGFR  
 
        Epidermal growth factor (EGF) is known to bind to its receptor (EGFR) with an 
equilibrium dissociation constant (KD) of 1-10nM in living cells. Quantitative binding 
experiments demonstrated that EGF binds to EGFR with two distinct dissociation 
constants: a minority (2%–5%) of high-affinity (KD~0.1nM) receptors and a majority 
(95%–98%) of low-affinity (KD~10nM) receptors. The two site binding leads to concave-
up type Scatchard plots (Schlessinger et al., 1986, 88). The structural identifications of 
different conformations of the EGFR extracellular regions suggested that the low affinity 
binding sites might represent receptors in the auto-inhibited conformation, whereas high 
affinity binding sites might be accounted for by receptors in the active, extended 
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configuration (Klein et al, 2003(6-11)). However, this hypothesis could not explain the 
concave-up character of the experimentally observed Scatchard plots. Furthermore, the 
data does not support the dimerization model, which assumes that receptors in the active 
conformation bind ligand with high affinity and form receptor-receptor dimers (Klein et 
al., 2003). Ozcan et al., argued that the concave-up curvature typical of an EGF binding 
Scatchard plot for wild type EGFR can be simulated only by including in the model a 
saturable high affinity external site for receptor dimers. Additionally, they argued that the 
so called low affinity EGF-binding sites seen in studies of the wild-type EGFR represent 
the interconverting tethered and extended (dimerizing) form of the receptor extracellular 
domain inferred from structural studies (Ozcan et al., 2006). Further studies by Macdonald 
et al., proposed that the concave-up Scatchard plots can be explained by including negative 
cooperativity in the system. The results from Macdonald et al., studies indicated that the 
affinity of EGF binding to the second site on a dimer (2.9nM) is 15-fold less than the 
affinity of EGF for binding the first site on a dimer (190pM). All of these studies supported 
that intracellular domain is required to account for concave-up Scatchard plots although it 
is clear that the extended configuration of the EGFR binds EGF with higher affinity than 
does the unextended configuration (Klein et al., 2003). All the above mentioned studies 
were carried in cells.   
        In non-cellular studies using soluble extracellular EGFR, the binding experiments and 
structural data suggest that EGF can bind to the sEGFR in at least two separate types of 
binding events (Lemmon et al., 1997). However, the generated Scatchard plots were not of 
concave-up character (Klein et al., 2003). In previous Biacore studies using soluble 
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extracellular EGFR, the apparent KD for EGF binding was reported to be 100-400nM 
(Wade et al., 2002, Iyer et al., 2007, Ferguson et al., 2003). Wade et al., reported that 
analysis of equilibrium binding data in Scatchard format for Biacore studies of 
EGF/sEGFR interaction gave an excellent linear fit (R=0.992) and indicated a KD of 
292nM but the curves did not fit ideally to a 1:1 Langmuirian model. A better fit was 
obtained with a model that comprised a small percentage of high affinity component 
indicating two independent binding events. The presence of high affinity was also 
suggested from Biacore solution competition data and fluorescence anisotropy experiments 
yielding biphasic Scatchard plots (Domagala et al., 2000).  
        Based on the previous Biacore studies, we designed our experiment for EGF/sEGFR 
interaction such that it closely imitates the physiologically active system of cell. We aimed 
to reproduce the literature binding kinetics and tried to explore further into the concepts of 
multiple binding events. A summary of the previous studies is given in Table 2.  
 
Table 3.2-1  Experimental systems used for EGF/EGFR interaction 
Reference Analyte Ligand Type of 
Study 
Interaction 
type 
Results 
(Scatchard 
Plot) 
Schlessinger 
et al., 1986, 
88. 
EGF EGFR In cells Heterogeneous Curvilinear 
Domagala et 
al., 2002 
hEGF sEGFR Biacore Heterogeneous Biphasic 
Wade et al., 
2000 
sEGFR mEGF Biacore Heterogeneous Linear 
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3.3  Review of previous studies on Cetuximab binding to EGFR 
 
        Cetuximab is a chimeric monoclonal antibody of the immunoglobulin G1 (IgG1) class 
that is directed against the human epidermal growth factor receptor (EGFR) and binds to 
extracellular domain of the receptor with high specificity. Cetuximab has been developed 
jointly by Merck, KGaA, and ImClone Systems Incorporated/Bristol-Myers Squibb for the 
treatment of several types of human cancer that express EGFR, including colorectal cancer, 
squamous cell carcinoma of the head and neck, nasopharyngeal cancer, pancreatic cancer, 
ovarian cancer, and non-small cell lung cancer.  
        Biacore binding studies of Cetuximab Fab fragment with sEGFR have shown a 
simple 1:1 Langmuir binding with an apparent KD of 2.3±0.5nM (Li et al., 2005). In this 
experiment, Cetuximab Fab fragment was immobilized and sEGFR was made to flow on 
the surface. In the studies carried over by Tikhomirov et al, sEGFR was immobilized on 
the sensor surface and Cetuximab was used as analyte. These studies reported binding in 
both high as well as low sEGFR surface density scenario. Low immobilization levels of 
sEGFR were used to represent monovalent binding conditions and high immobilization 
levels were used to show bivalent binding conditions. In studies carried over by Goldstein 
et al., an equilibrium dissociation constant of 0.2nM was reported using Biacore studies 
where sEGFR was amine coupled to the surface and Cetuximab was the analyte. 
        In our studies, we tried to imitate the system close to that in living cells, immobilizing 
sEGFR to the surface. Also, we used two different surface densities (one higher and the 
other lower) to compare the binding of Cetuximab to explain avidity effects on the surface. 
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We reported the kinetic dissociation rate constant of Cetuximab/sEGFR interaction for the 
first time in our studies.  
 
3.4  Considerations for Biacore experiments 
 
        The following constraints must be considered while designing a binding experiment 
on Biacore and analyzing the data obtained. 
 
3.4.1  Mass Transport 
 
        Biacore has a flow cell which consists of a sensor surface on top of which one of the 
interactants (ligand) is immobilized. The other interactant (analyte) is passed over the flow 
cell and binding is determined by the optical system.  
        In Biacore, analyte is transported by diffusion and flow to the sensor surface, where it 
reacts with the immobilized receptor (Myszka et al., 1998). Under laminar flow conditions 
used in Biacore, the rate of transport of the analyte to the surface is proportional to the 
cube root of the flow rate, and is also influenced by the dimensions of the flow cell and the 
diffusion properties of the analyte (Jason-Moller et al., 2006). The interaction is reaction 
limited when the transport of analyte to the surface is much faster than the rate of analyte 
association with the ligand. The observed binding here will be determined by the kinetic 
rate constants (Jason-Moller et al., 2006). On contrary, the binding is mass transport 
limited when the rate of analyte transport to the surface is slower than the reaction rate of 
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analyte to the ligand. This may lead to partial or no kinetic information of the binding. 
Optimal assay conditions have to be determined to minimize mass transport limitations to 
get reliable kinetic information. 
        From the Biacore studies, it was determined that mass transport limitations majorly 
depend on two factors: surface density of the ligand and flow rate of the analyte to the 
surface. As the receptor density on the sensor surface is increased, the binding reaction at 
the surface speeds up, and the binding kinetics become transport limited (Myszka et al., 
1998). High flow rates help in delivering consistent amount of sample to the surface. 
Hence, the kinetics is best studied under conditions of high flow rates and low surface 
binding capacity. In practice, this translates to using ligand densities that result in a 
maximum analyte binding response no greater than 50 to 150RU and flow rates greater 
than 30µl/min (Jason-Moller et al., 2006). 
 
3.4.2  Analyte Concentrations 
 
        Analyte concentrations play an important role in accurately determining the 
equilibrium or association rate constants correctly. The surface is said to be 50% saturated 
with analyte at the concentration equal to equilibrium dissociation constant KD. It is 
recommended that the concentrations cover a full range of “binding curves” showing 
barely binding of analyte to “saturation binding”. Reliable detailed kinetic analysis 
requires data from four to six analyte concentrations, spanning the range of 0.1 to 10 times 
KD (Jason-Moller et al., 2006). Analytes should be in the same buffer as the continuous 
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flow buffer to minimize bulk refractive index differences that can lead to low signal-to-
noise ratios. This is often most easily achieved through dilution of a concentrated analyte 
stock into running buffer. Kinetic assays should include a series of start-up cycles using 
buffer as analyte to equilibrate the surface as well as cycles with zero concentration of 
analytes as part of the concentration series for the purposes of reference subtraction 
(Myszka et al., 1999). Although it is not necessary to reach equilibrium, it is recommended 
that the association times used be sufficient for at least one analyte concentration to reach 
steady state. To accurately determine dissociation rate constants, a measurable decrease in 
signal should occur during the dissociation period (Jason-Moller et al., 2006). 
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CHAPTER 4  Experimental Background 
 
4.1  Surface Plasmon Resonanace 
 
        Surface Plasmon Resonance (SPR) is a relatively new technique used to measure 
biomolecular interactions in real time. This is done in a label free environment, while one 
of the interactants is immobilized on to the sensor surface and the other is passed over the 
surface. The association and dissociation of the interactants are measured in resonance 
units (RU) and plotted as a Sensogram. 
 
4.1.1  Principle of SPR 
 
        SPR is a phenomenon that occurs in thin conducting films at an interface between 
media of different refractive indices. In the Biacore instrument, the conducting film is thin 
layer of gold, and the media are the glass of the sensor chip and the sample solution. When 
a plane polarized light is incident onto the reflecting interface, under conditions of total 
internal reflection, an electric field intensity known as an evanescent wave is generated. 
This evanescent wave is exponentially detenuating with distance from the surface. At a 
specific incident angle and energy (wavelength), the incident light excites plasmons in the 
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gold film and SPR is seen as a drop in the intensity of the reflected light due to the 
resonance energy transfer between evanescent wave and surface plasmons. The resonance 
conditions are influenced by the material absorbed onto the thin metal film and the SPR 
signal depends on the refractive index of solutions in contact with the surface.  
          
Figure 4.1-1  Demonstration of Surface Plasmon Resonance. The binding of analyte shifts the SPR angle 
from position I to II. 
  
        In Biacore, the immobilized molecule on the surface is called the ligand and the 
molecule that flows over the surface is called the analyte. As analyte binds to the ligand, 
there is accumulation of protein on the surface which results in an increase in the refractive 
index. This change in refractive index is measured in real time and plotted as response or 
resonance units (RU) versus time. This plot is called a Sensogram and gives information 
on kinetics, affinity, binding specificity and concentration profiles. The technology allows 
determination of these parameters with analytes ranging in size from about 150 to 106 
g/mole (Dalton). 
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Figure 4.1-2  Sensogram 
 
4.2  Instrumentation 
 
        The Biacore instrument is composed of three main units: the optical system, a liquid 
handling system and the biosensor chip. The instrument is connected to a PC running 
Biacore, where the results are presented in real time as a Sensogram. 
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Figure 4.2-1  Three corner stones of Biacore technology 
 
4.2.1  Optical System 
 
        The optical system is responsible for generation and detection of the SPR signal. It 
detects all surface changes in refractive index as the mass changes in the aqueous layer 
close to the sensor chip surface. The optical unit has a glass prism on to which the glass 
slide of the sensor chip is kept in contact. A good optical coupling between the prism and 
sensor chip is ensured by a silicone opto-interface. Light is focused through the prism on to 
the sensor chip surface from a near-infrared light-emitting diode (LED), giving a fixed 
range of incident light angles. Light reflected from the sensor chip is monitored by a linear 
array of light-sensitive diodes covering the range of incident light angles. By using a 
wedge of incident light and a fixed array of detectors, the SPR angle is monitored 
accurately in real time (Bia technology handbook).  
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4.2.2  Liquid Handling System  
 
        The liquid handling system with precision pumps and an integrated microfluidic 
cartridge (IFC) in Biacore maintains a constant flow of sample and buffer over the sensor 
chip surface. The autosampler in the system helps in transferring, diluting and mixing 
samples, injecting samples into the IFC. One of the two pumps maintains a continuous 
flow of liquid through the detector flow cell while the other assists in the working of the 
autosampler. Samples are transferred through a needle from the autosampler into the IFC, 
which connects with the flow cells. The microfluidic system allows single or multichannel 
analysis in up to four flow cells. One of the flow cells can be used as a true reference 
during sample injection, allowing blank-subtracted data to be presented on screen during 
analysis. The data obtained thus enhances the signal quality and maximizes the resolution.  
 
4.2.3  Sensor Chip 
 
        The Biosensor chip is a glass slide coated with thin layer of gold, creating the 
physical conditions required for generating an SPR signal. This forms the base for the 
attachment of a range of specialized surfaces designed to optimize the binding of various 
molecules (Malmqvist et al., 1999). On most sensor chips, a matrix of carboxymethylated 
dextran layer is covalently attached to the gold surface forming a surface layer of 
approximately 25-100nm thick. The dextran layer maintains a hydrophilic environment 
suitable for a variety of protein interactions and helps in covalent immobilization of bio 
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molecules. The sensor chip can be divided into four flow cells and each flow cell can be 
used independently (Wei et al., 2004). 
        Sensor chip CM5 is the most commonly used versatile chip which supports 
immobilization of wide range of ligands from small organic molecules to proteins, nucleic 
acids and carbohydrates. Molecules are covalently coupled to the sensor surface via amine, 
thiol, aldehyde or carboxyl groups. The chip is mounted on a plastic support frame that is 
protected by a plastic cassette.  
        Some other sensor chips include sensor chip SA which is used to capture biotinylated 
peptides, proteins and DNA, sensor chip NTA which is used to capture ligands via metal 
chelation, sensor chip HPA which is for membrane biochemistry and the study of 
membrane associated receptors. 
  
4.3  Immobilization 
 
        Biomolecules for interaction can be attached to the sensor surface using two different 
approaches: Covalent immobilization and Capturing methods. 
 
4.3.1  Covalent Immobilization 
 
        Covalent immobilization is the most commonly used approach for attaching the 
ligand to the dextran matrix on the sensor surface. The various covalent immobilization 
chemistries used are: Amine coupling, which couples amine groups on the ligand to the 
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carboxyl groups on the dextran matrix; Thiol coupling, which is used when there can be 
thiol-disulfide exchange between thiol groups and active disulfides introduced on either the 
ligand or the surface matrix; Aldehyde coupling, which is used when there can be reaction 
between hydrazine or carbohydrazide groups introduced on the surface and aldehyde 
groups obtained by oxidation of carbohydrates in the ligand.  
        Covalent immobilization may have limited stability under certain conditions, although 
it generally results in stable attachment of ligand to the surface under the buffer conditions 
normally used for interaction analysis and regeneration. Also, it might involve chemical 
modification of the ligand which can potentially affect the analyte-binding activity. But 
most ligands can be immobilized without losing activity by one or the other chemistry.  
 
4.3.2  Capturing Approaches 
 
        Capturing is the best alternative approach when covalent immobilization results in 
loss of ligand activity or is unsuitable for other reasons. The capturing molecule is 
covalently attached to the matrix to which the ligand is immobilized. The ligand 
interaction with the capturing molecule should have a high affinity so that the ligand does 
not detach from the molecule during analysis. Capturing approach does not introduce 
conformational changes in the ligand and the orientation of ligand is in a specific direction. 
But capturing approaches consume more ligand when fresh material has to be captured for 
each analysis since some ligand dissociates from the surface during regeneration. The 
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common capturing approaches are streptavidin- or avidin-biotin capture, antibody-based 
capture, and capture of tagged proteins. 
 
4.4  Amine Coupling 
 
        Amine coupling is used to immobilize molecules which contain amine groups. This is 
the most generally used coupling chemistry since most of the biomolecules contain amine 
groups. Firstly, carboxyl groups on dextran surface are activated by passing a mixture of 
EDC and NHS to yield reactive ester groups. Ligand is then passed over the surface where 
the esters spontaneously react with primary amine groups or other nucleophilic groups on 
the ligand and link it covalently to the dextran matrix. Injection of ethanolamine after 
ligand immobilization deactivates the remaining active ester groups on the surface and 
removes non-covalently bound ligand. Typical Sensogram of amine coupling is shown in 
Figure 4.4-1. 
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Figure 4.4-1  Illustrative graph of Amine coupling 
 
4.5  Kinetics 
 
        Biacore has several applications which include defining the characteristics of proteins 
in terms of their specificity of interaction with other molecules, their affinity of binding to 
other molecules, and the rates at which they interact (Karlsson et al., 2006). Biacore 
system also provides accurate concentration measurements. 
        The application of interest in this project is kinetics since it provides dynamic binding 
information as in actual cellular processes. As the analyte binds to the ligand, there is 
increase in mass at the sensor surface which is recorded as association phase and as analyte 
dissociates from the ligand, the decrease in mass at the surface is recorded as dissociation 
phase in the Sensogram. When the rate of association and rate of dissociation are equal, 
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there is equilibrium established, which is marked by steady state in the Sensogram. For 1:1 
Langmuir interaction, the dissociation constant, KD, is the ratio of kinetic rate constants, 
kd/ka. A lower value of KD represents greater affinity of the ligand-analyte interaction. 
        For kinetic applications, the ligand immobilized has to be low to avoid mass transport 
effects. For best kinetic results, the maximum analyte binding capacity, Rmax is in the range 
50-150RU. The level of ligand to be immobilized is calculated using the manufacture’s 
recommended formula, Rmax = (MWa/MWL) * RL * Sm. The concentration range of analyte 
is 0.1KD to 10KD. 
 
4.6  Regeneration Scouting 
 
        The analyte has to be completely dissociated from the ligand to start a new analysis 
cycle. The extent of dissociation in running buffer varies with the type of analyte and how 
strong it binds to the ligand. A regeneration solution has to be passed over the surface to 
remove the bound analyte from the ligand of the surface. The conditions for regeneration 
have to be such that the ligand over the surface is not damaged or does not lose activity. 
Regeneration scouting method helps in finding suitable regeneration conditions for the 
ligand, which is determined for our system as described in Chapter 5 below. 
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CHAPTER 5  Materials and Methods 
 
5.1  Materials 
 
        SPR measurements are performed using Biacore 3000 system. The antibodies, buffers 
and reagents used for the experiments are listed below. 
 
5.1.1  Antibodies 
 
        The receptor sEGFR was used as the ligand and the growth factor EGF and the cancer 
drug Cetuximab were used as analytes to study the interaction. Also the binding interaction 
of sEGFR with a peptide (P-13), designed specifically for this target was also studied. The 
human recombinant sEGFR was purchased from Research Diagonostic Inc and EGF was 
purchased from Sigma. Another 100mg/ml of EGF was purchased from BD Biosciences 
for additional experiments. The Cetuximab was purchased from the pharmacy of Massey 
Cancer Center. The P-13 was synthesized using CEM® Automated Microwave Peptide 
Synthesizer. 
 
5.1.2  Buffers and Stock Solutions 
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        The buffers and other reagents used for Biacore experiments are listed in the Table 
5.1-1 below. All solutions were made up of DI H2O from Millipore.  
 
Table 5.1-1  Buffers and Stock solutions for Biacore 
          Name of the Solutions                          Components 
HBS-EP Aqueous buffer containing 0.01 M HEPES pH 7.4, 0.15 
M NaCl, with 3mM EDTA and 0.005% Surfactant P20.  
Amine Coupling Solutions EDC (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
hydrochloride); and NHS (N-hydroxysuccinimide); and 
Ethanolamine 1M. 
Regenerations Solutions Glycine 2.0; or Glycine 2.5; or NaOH 10mM; or NaOH 
50mM; 
Ligand stock solution 10mM NaAc pH 5.2±0.1 
BIAnormalizing solution  70% glycerol 
BIAdesorb solution 1 0.5% sodium dodecyl sulphate (SDS) 
BIAdesorb solution 2 50mM glycine-NaOH pH 9.5 
BIAdisinfectant solution Sodium hypochlorote with 8-12% active chlorine 
 
5.1.3  Reagents and Stock Solutions for Peptide Synthesis 
 
        The reagents and other solutions used for peptide synthesis and purification are listed 
in the Tables 5.1-2, 5.1-3, 5.1-4 below. All amino acid solutions are prepared in DFM. 
 
Table 5.1-2  Reagents and Stock Solutions for peptide synthesis.  
          Name of the Solutions                          Components 
Main Wash  DFM (N, N-Dimethylformamide); and DCM 
(Dichloromethane). 
Activator 8.53g HBTU dissolved in 45ml DMF. 
Activator Base A solution of 17.4ml DIEA (N, N-
Diisopropylethylamine) mixed with 32.6ml of NMP (1-
Methyl-2-Pyrrolidone).  
Deprotect A solution of 100ml piperidine, 400ml DFM (N, N-
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Dimethylformamide) and 6.75g HoBt.  
Capping mix 20% of Acetic anhydride in DMF (4ml of Acetic 
anhydride in 16ml DMF). 
Cleaving mix A solution of 250µl DODT (3, 6-Dioxa-1, 8-octane-
dithiol), 250µl TIS (Triisopropylsilane), 250µl H2O 
mixed in 9.25µl of TFA (Trifluoroacetic acid). 
Peptide precipitate mix Diethyl ether (or cold ether).  
 
Table 5.1-3  Reagents and buffers used for protein purification (HPLC). 
          Name of the Solutions                          Components 
B.conc  0.1% TFA in MeCN (Acetonitrile).  
A. conc 0.1% TFA in DI H2O. 
 
Table 5.1-4  Solutions used for MALDI Mass Spec. 
          Name of the Solutions                          Components 
Matrix   500µl of 0.1% TFA mixed in the solution of 10mg 
crystallized CHCA and 500ul Acetonitrile.  
 
5.2  Equipment 
 
5.2.1  Biacore 3000 
 
        The binding studies of the proteins and antibodies were carried out using Biacore 
3000 instrument from GE Healthcare. The experiments were carried out at 25ºC with a 
data collection rate of 1Hz. The running methods were created using the Biacore 3000 
control software 3.0. The Sensograms were evaluated using BIAevaluation 3.0 software 
provided by the manufacturer. Maintenance of the instrument was performed according to 
the supplier’s instructions. 
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5.2.2  CEM Microwave Peptide Synthesizer 
 
        Liberty-Automated microwave peptide synthesizer from CEM Corporation was used 
to make the peptide P-13. This instrument uses microwave energy to drive biochemical 
reactions resulting in higher purity peptides made 10 times faster than by conventional 
methods. All amino acid bottles and reagent bottles were cleaned and back flushed before 
starting the synthesis.  
 
5.2.3  Other Instruments 
 
        MALDI Mass Spectrometer was used to check the mass of the peptide synthesized. 
The data was collected and analyzed using the Mass Lynx software provided by the 
manufacturer. HPLC (High Performance Liquid Chromatography) was used to purify the 
peptide. The software used for analysis of data was LC solutions provided by the 
manufacturer. The Eppendorf Microcentrifuge was used to filter the peptide samples for 
HPLC purification. The samples were filled in microcentrifuge vials and were centrifuged 
at 13.5rpm speed for 1min. Rotary Evaporator from Fisher Scientific was used to remove 
solvents from the peptide solution after purification.  
 
5.3  Peptide Synthesis 
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        The peptide synthesis was carried out using Automated Microwave Peptide 
Synthesizer from CEM Corporation. All amino acids and reagents needed for synthesis 
were freshly prepared before the start of the experiment.  
 
5.3.1  Synthesis of P-13 
 
        The amino acid sequence was input to the instrument software which subsequently 
calculates the amounts of reagents required for the synthesis. The amino acids were 
prepared dissolving the calculated amounts of respective samples in the given volumes of 
DMF as recommended by the CEM program. The activator used was HBTU dissolved in 
DMF and the activator base was a solution of DIEA and NMP. A solution of piperidine, 
DMF and HOBt was used as deprotect mix and 20% Acetic acid in DMF was used as a 
capping mix for the synthesis. The resin used was Fmoc-PAL-PEG. The synthesis ran for 
9hrs for this 13-residue peptide. 
 
5.3.2  Washing and Cleaving the Peptide 
 
        The resin having the peptide was washed with DCM after filtering it out from DFM. 
The excess DCM was filtered out and the resin with peptide was subject to cleavage in a 
solution of DODT, TSI, H2O and TFA. The resinous solution was filtered and the filtrate 
was mixed with cold ether which was centrifuged to give out a precipitate and stored at -
20°C as peptide.  
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5.3.3  Purification of the peptide 
 
        High Performance Liquid Chromatography (HPLC) was used to purify the peptide 
from other salts after cleaving it from the resin. A peptide solution of 20mg/ml 
concentration was made by dissolving a pinch of the peptide in 0.1%TFA & H2O. An 
analytical procedure was carried out on HPLC to determine the gradient of mobile phase 
component “B” for peptide extraction. After obtaining the gradient, the separation was 
carried out on a large scale and the purified solution was tested on Mass Spec to reconfirm 
the presence of the peptide by checking the mass of the obtained sample. The mass 
acquisition range specified was from 800-3000Dalton. A rotary evaporator was used to 
remove solvents by evaporation from the peptide solution. The obtained peptide is weighed 
using a mass balance and stored at -20°C for Biacore applications.        
 
5.3.4  Concentration of the peptide 
 
        Biophotometer was used to determine the concentration of the peptide at A280nm, since 
using a mass balance has not proven to be an accurate way to get the weight of the peptide; 
the peptide mass synthesized (~mg) is too small and even a minute quantity of water or 
other substances sticking to the vial would affect the accuracy of weight shown. The 
peptide was dissolved in 1ml DI H2O and 3µl of H2O was used as reference blank. Peptide 
volume of 3µl was given as sample and the absorbance value was displayed on the screen. 
The concentration of the peptide is then calculated using the equation A=ebc (Beer-
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Lambert law), where, A is the absorbance of the sample, b is the path length, c is the 
concentration in mol/l and e is the extinction coefficient of the peptide which is calculated 
as referenced in Kibbe WA et al., 2007. Multiplying the calculated concentration with the 
molecular weight of the peptide (1688g/mol) gives the concentration of the peptide in g/l 
which can be converted to mg/ml.     
 
5.4  Surface Preparation 
 
        A research grade CM5 sensor chip from Biacore was used to immobilize ligand on 
flow cell 2 or 4 using flow cell 1 or 3 as reference accordingly. The bare chip was 
conditioned by passing 50mM NaOH for five cycles for 1min through all the flow cells. 
This procedure removes all loosely bound dextran material from the surface. Then the chip 
was normalized according to the supplier’s instructions. This gives maximum sensitivity of 
the chip. The sensor surface and sample blocks were maintained at 25°C.   
  
5.4.1  Preparation of sEGFR as ligand 
 
        The human recombinant soluble EGFR (purchased from Research Diagnostic Inc) 
was used as the ligand. The ligand was diluted with 10mM sodium acetate buffer to a 
concentration of 25µg/ml. The ligand was diluted to give a solution of pH 5.2±0.1 which 
falls in the required range (3.5 and isoelectric point of the ligand). The carboxymethylated 
dextran on the sensor chip is negatively charged above the pH 3.5 and electrostatic 
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attraction provides an efficient means for concentrating positively charged ligands on the 
surface. Hence, the ligand was prepared in 10mM NaAc (pH 5.2±0.1) to give a final 
concentration of 25µg/ml (Iyer et al., 2007). This concentration was used for the binding 
studies of all the three analytes- EGF, Cetuximab and peptide P-13.  
 
5.4.2  Immobilizing sEGFR on CM5 
 
        The amine coupling kit from Biacore was used for the procedure. The EDC and NHS 
solutions were prepared according to the manufacturer’s instructions. The ligand level to 
be immobilized was determined using the formula as discussed in Chapter 4, 
Rmax = (analyte MW/ligand MW) * Stoichiometry * RL. 
        The binding capacity of the surface depends on the ligand immobilization level. Here 
RL is the immobilization level of the ligand which determines the maximum response, 
Rmax. For the experiment, the Rmax has been considered to be in the range 50-150RU. Here, 
the molecular weight of sEGFR is 82kD. The molecular weights of EGF, Cetuximab and 
the peptide P-13 are 6kD, 152kD and 1.688kD respectively.  Fitting in the values of 
molecular weights for the given proteins in the equation, a suitable range for the 
immobilization level of sEGFR was determined for all three analytes. Considering only 
60% of the ligand is active on the surface, the immobilization level is scaled up 
accordingly. Hence an immobilization levels in the range 2500-5500RU for EGF, about 
100-400RU for Cetuximab and about 2500-4000RU for P-13 were achieved.  
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        The sensor chip has four flow cells out of which flow cells 1 or 3 were used as 
reference cells and immobilization was done on flow cells 2 or 4. Immobilization was 
carried out in two ways: Using ‘Aim for Immobilized level’ wizard or using ‘Specify flow 
rate and injection time’ wizard. The first few experiments were carried out using ‘Aim for 
immobilized level’ wizard with target RU set to 2500RU for EGF-sEGFR interaction. The 
later were carried out specifying flow rate and injection time. The flow rate and injection 
time was specified for all Cetuximab-sEGFR and P-13-sEGFR experiments. The flow rate 
and injection time were adjusted such that the target RU (as per calculations above) was 
reached.  
 
5.5  Kinetic Analysis of protein-protein or peptide-protein interactions 
 
        The kinetic studies of sEGFR-EGF, sEGFR-Cetuximab and sEGFR-P-13 were carried 
out using the kinetic analysis wizard. HBS-EP was used as the running buffer. 
 
5.5.1  EGF Interaction 
 
        EGF was serially diluted in sterile HBS-EP buffer with the dilution factor of 2 
between each concentration. The concentration range used was 1000nM to 10nM and a 
zero concentration sample was included for reference subtraction. The analyte 
concentrations were adjusted such that the lowest concentration barely shows binding to 
the ligand and highest concentration reaches saturation. The wizard template had the run 
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order sorted from low analyte concentration to high analyte concentration. The samples 
were injected over the surface at a flow rate of 30µl/min with a 3min association pulse and 
15min of dissociation, without the need for a regeneration step (Iyer et al., 2007).   
 
5.5.2  Cetuximab Interaction 
 
        The drug Cetuximab, also called C225 was diluted in sterile HBS-EP buffer to a 
series of concentrations. The analyte concentrations for analysis ranged from 0.2nM to 
30nM with a dilution factor of 2 between each concentration. Also, a high concentration 
sample of 100nM and a zero concentration (plain buffer) sample were included for 
analysis. The samples were run from low to high order at a flow rate of 30µl/min with 
2min association and 10min dissociation. In order to find the optimal conditions for 
dissociation of the ligand-analyte complex, a regeneration scouting method was run with 
glycine as regeneration solution at three different pH values. The solutions were tested 
from mild to harsh conditions. The solutions used were glycine pH 3.0, glycine pH 2.5, 
glycine pH 2.0. It was observed that the regeneration was best when glycine pH 2.5 was 
used as regeneration solution. In this case, the ligand surface returned to within 1% of its 
initial RU value. Hence, the surface was regenerated with a single injection of 10mM 
glycine (PH 2.0) for 1 min after dissociation and a stabilization time of 1min was included.   
 
5.5.3  Peptide Interaction 
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        The peptide P-13 was initially diluted using HBS-EP buffer to higher concentrations 
and tested on the sensor chip immobilized with sEGFR for binding. The concentrations 
were increased in the next subsequent runs when significant binding was not observed. The 
regenerations conditions were determined by performing regeneration scouting with 
regenerations solutions glycine at pH 3.0, pH 2.5, pH 2.0, pH 1.5 and 10mM NaOH. The 
solutions were tested from mild to harsh conditions. After determining the concentration of 
analyte which gives good binding to the chip and a suitable regenerations solution which 
dissociates the complex, analyte dilutions were carried out with a minimum concentration 
of 200uM and maximum concentration of 1000µM. A zero concentration sample was 
included for reference subtraction. Kinetic analysis wizard was run with the series of 
concentrations with an association time of 5mins and dissociation time of 15mins at flow 
rates 30µl/min. The surface was regenerated with a single injection of 10mM NaOH for 
30seconds after dissociation and a stabilization time of 1min was included.  
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CHAPTER 6  Results and Discussion 
 
        The results of binding kinetics studies of antibodies EGF, Cetuximab and P-13 with 
sEGFR carried on Biacore are presented in this chapter along with mass and purification 
data of the peptide P-13. Comparisons to previously reported results are given for the EGF-
sEGFR system and Cetuximab-sEGFR system. We demonstrate that our Biacore results 
for the EGF-sEGFR system are consistent with cell culture results. 
 
6.1  Synthesis of P-13 
 
6.1.1  Calculating the mass of P-13 
 
        The mass of the peptide was calculated using peptide mass calculator v3.2 (Jef 
Rozenski (1999)) available on web by inputting the peptide sequence. The peptide mass 
was calculated considering that the N-terminal of the peptide was acylated and C-terminal 
was an amide bond. The calculated peptide mass was 1688.737 Dalton.  
 
6.1.2  Determining P-13 mass using MALDI Mass Spec 
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        MALDI Mass Spectrometer was used in molecular weight confirmation of the peptide 
P-13. The peptide was tested on MALDI before and after purification. Samples to be 
analyzed were prepared at ratio 2:8 peptide digest to matrix (crystallized α-Cyano-4-
hydroxy-cinnamic acid, CHCA), and subsequently dried on a stainless steel MALDI plate. 
The mass data of the P-13 before purification (data not shown) and mass data after 
purification of P-13 using HPLC was consistent and confirms the presence of the peptide 
P-13. The mass data after purification is shown in Figure 6.1-1.    
 
Figure 6.1-1  Data from Mass Spec for purified P-13. 
 
        The purified peptide from HPLC was collected in a vial and the solvents were 
evaporated using a rotary evaporator. The weight of the empty vial was recorded and the 
weight of the vial after rotary evaporation was recorded. The weight of the actual peptide 
was determined by carrying subtraction between the two weights obtained. One ml of DI 
H2O was added to the known weight of the peptide formed and Mass Spec was run on the 
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sample. Also, the sample was tested for concentration on Biophotometer since mass 
balance can show drastic variations from the actual weight even with a minute quantity of 
other solvent present in the sample. The data of the Mass Spec is shown in the Figure 6.1-
2. This confirms the presence of the peptide after rotary evaporation.   
 
 
Figure 6.1-2  Data from Mass Spec for purified P-13 after solvent evaporation. 
 
6.1.3  Purification of P-13 
 
        The peptide purification was carried on HPLC as described in Chapter 5. The peptide 
was recovered by gradient elution using a linear 50min gradient at a flow rate of 
0.44ml/min. Detection was by absorbance at 280nm. Fractions were collected and analyzed 
using Mass Spectrometer for peptide mass. The fraction between 8-8.5min was identified 
to contain the peptide. The purification was then carried out on a large scale at a flow rate 
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of 10ml/min and the peptide was collected between 18-19mins. The peptide peak on HPLC 
is shown in Figure 6.1-3. 
 
 
Figure  6.1-3 Chromatogram obtained from purification of P-13 using HPLC. The fragment was eluted 
between 18.5-19.6min, detected at wavelength 280nm. 
 
6.2  Immobilization of sEGFR on CM5 sensor chip 
  
        The immobilization of sEGFR on CM5 sensor chip was done using amine coupling as 
described in the previous chapter. The immobilization levels (in RU) varied with analyte 
used for analysis.  
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Figure 6.2-1  Immobilization of sEGFR using amine coupling. Surface is activated with EDC/NHS mixture 
before the ligand is injected to the surface and ethanolamine is used to deactivate the surface after ligand 
binding. 
 
        The sEGFR immobilization for EGF interaction studies was between 3000-5500RU. 
Cetuximab interaction studies were carried out with sEGFR immobilization level between 
100-400RU. The immobilization level for peptide P-13 studies was between 2500-
4000RU, each calculated according to the Rmax equation as described in Chapter 4. A 
representative sEGFR amine coupling Sensogram is shown in Figure 6.2-1.  
 
6.3  Kinetic analysis 
 
        The data obtained from binding studies of sEGFR with antibodies EGF, Cetuximab 
and P-13 are presented here.  
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6.3.1  Binding studies with EGF 
 
        The sEGFR ligand was immobilized on flow cell 2 using flow cell 1 as reference. For 
kinetic analysis, varying concentrations of EGF were passed over the sensor surface in 
order of increasing slope from the lowest concentration to the highest concentration. The 
running buffer was HBS-EP and the injected concentrations of EGF were 1000 (the curve 
with the highest RU), 500, 250, 125, 60, 30, 15 and 10nM. Data were analysed at the 
above mentioned concentrations of EGF with several densities of sEGFR (3357, 3700, 
5500RU) immobilized on the surface. The representative Sensograms of the evaluated data 
are presented in Figure 6.3-1 below. 
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Figure 6.3-1a  Kinetic analysis of EGF with sEGFR: Data fitted using 1:1 Langmuir binding model. Various 
concentrations of EGF were injected at 30µl/min over 3357RU immobilized sEGFR and reference surface 
(activated and deactivated by EDC/NHS and ethanolamine). Curves shown are reference subtracted.  
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Figure 6.3-1b  Kinetic analysis of EGF with sEGFR: Data fitted using heterogeneous ligand parallel 
interactions model. The data used is same as in Figure 6.3-1a. 
 
        The curves exhibit fast on and off rates and reach equilibrium binding rapidly. Both 
rate and equilibrium binding constants were determined fitting data using simultaneous 
ka/kd model (data fitted globally) as well as carrying over analysis of equilibrium binding 
data in Scatchard format. 
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Figure 6.3-2  Scatchard plot of EGF binding to sEGFR. Steady state binding data was obtained by plotting 
Req against concentration (shown in the right upper corner). Req/Conc was calculated and plotted against 
concentration for Scatchard plot. 
 
        The Scatchard plot of equilibrium binding data of EGF with the receptor sEGFR is 
shown in Figure 6.3-2. The data seem to show deviations from linearity which indicates 
that there are more than one independent binding events occurring.  
        The x-intercept in the Scatchard plot of Biacore data represents the maximum analyte 
binding capacity Rmax (~65 RU). For the immobilization of 3357RU, the theoretical Rmax 
came up to be 251 RU assuming 1:1 interaction of EGF with sEGFR. This suggests that 
only 25% of the biosensor surface was either active or had immobilized ligands in 
accessible orientations.  
        For all sEGFR surface densities, the data from the primary analysis showed a poor fit 
(R>0.2) to 1:1 Langmuir interaction model suggesting that more complex binding 
mechanisms were operative. The curve fitting to the heterogeneous ligand- parallel 
intereactions model was significantly better indicating two independent binding sites in the 
system. For 3357RU of sEGFR immobilization, one of the two binding sites was a low 
affinity binding site which contributed to 90% of the total binding with an apparent ka of 
3.75e5M-1s-1 and kd of 0.0406s-1, resulting in a calculated KD of 108nM which is in good 
agreement with the literature KD for EGF and sEGFR interaction, as shown in Table 6.3-1. 
The high affinity binding site is just 10% of the total binding and has a calculated KD of 
about 5.4nM. For 5500RU sEGFR surface density, the kinetic rate constants agreed 
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approximately to that of the previously obtained values except that the high affinity 
binding increased to 16% of the total binding. 
        Mass transfer limitations were tested with higher concentration of EGF (100nM) at 
flow rates 5µl/min, 15µl/min and 75µl/min. Figure 6.3-2 shows a representative 
Sensogram of EGF kinetics at three different flow rates. The kinetics of the binding of 
EGF to sEGFR changed less than a few percent with changes in flow rate, indicating that 
the reaction is not mass transfer limited.  
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Figure 6.3-3  Data from Mass transfer control experiment. Kinetics of 100nM EGF at different flow rates 
(5µl/min, 15µl/min, and 75µl/min) was determined. Kinetics of EGF binding was same at all flow rates.  
 
        The equilibrium binding constants are reported in the Table 6.3-1 for EGF and 
sEGFR interaction. Comparisons are also given with that of literature values.   
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Table 6.3-1  Summary table for equilibrium binding constants for EGF/sEGFR interaction. 
Low Affinity Binding High Affinity Binding  Ligand Analyte 
KD (nM) kd (s-1) KD (nM) kd (s-1) 
Our Studies 
(Biacore) 
sEGFR EGF 115±10 0.04 13±8 0.002 
Iyer et al., 2007 
(Biacore) 
sEGFR EGF 110 - - - 
Shiqing Li et al., 
2005 (Biacore) 
EGF sEGFR 130±3 - - - 
Wade et al., 2002 
(Biacore)  
mEGF sEGFR 400 0.042 28 0.02 
Domagala et al., 
2000 
rhEGF sEGFR 439 0.066 60 0.013 
J Schlessinger et 
al., 1986 (In cells) 
EGFR EGF 1-10 - 0.01-0.1 - 
 
6.3.2  Binding studies with Cetuximab 
 
        Cetuximab was used in increasing concentrations run from low order to high using 
kinetic analysis. HBS-EP buffer was used to make serial dilutions and the concentrations 
injected were 50, 20, 5, 2, 1, 0.2, 0.02nM. A 0nM sample was also injected for reference 
subtraction. The interaction was tested for mass transfer limitations using 0.2nM and 20nM 
concentrations at flow rates 5µl/min, 15µl/min and 75µl/min and the data obtained did not 
seem to be affected with change in flow rates indicating the reaction is not mass transport 
limited (data not shown). The data was analysed with varying concentrations of Cetuximab 
and two different surface densities of sEGFR (100 and 300RU). The representative 
Sensograms of evaluated data are presented in Figure 6.3-4. 
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Figure 6.3-4  Kinetic analysis of C225 with sEGFR: various concentrations of C225 were injected at 
30µl/min over 100 RU immobilized sEGFR and reference surface (activated and deactivated by EDC/NHS 
and ethanolamine). Curves shown are reference subtracted.  
 
        The Sensograms fitted using 1:1 Langmuir binding model showed significant 
deviations for higher surface density (data not shown). As the surface density was 
decreased to 100RU, 1:1 Langmuir binding model (data not shown) showed a better fit 
except that the higher and lower concentrations for analyte still showed deviations. 
However, the curve fitting was good using Bivalent analyte model (where the analyte can 
bind to two ligands simultaneously on the surface) for all surface densities. The curves 
showed a slow dissociation with apparent ka of 8.36e5M-1s-1 and kd of 1.81e-3s-1, resulting 
in a calculated KD of 0.2nM which is in good agreement with the literature. 
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        The equilibrium binding constants for Cetuximab and sEGFR interactions are 
reported in the Table 6.3-2. Comparisons are also given with literature values. 
Table 6.3-2  Summary table for equilibrium binding constants for Cetuximab/sEGFR interaction.  
 KD (nM) kd (s-1) 
Our studies (Biacore) 0.15±0.05 0.002 
Shiqing Li et.al, 2005 (Biacore) 2.3±0.5 - 
Neil I. Goldstein et al., 1995 (Biacore) 0.2 - 
 
 
6.3.3  Binding studies with P-13 
 
        P-13 was used in increasing concentrations run from low to high order using kinetic 
analysis wizard. HBS-EP buffer was used to serial dilutions and peptide concentrations of 
1000, 800, 600, 400, 500, 300 and 200µM were injected to determine steady state binding 
affinity. The interactions were tested for mass transfer limitations using 400µM 
concentration at flow rates 5, 15 and 75µl/min and it did not seem to be affected by mass 
transport.  
        The Sensograms showed fast dissociation and the curves did not start to plateau to 
determine steady state binding affinity. The highest concentration (1000µM) seemed to 
show nonspecific binding and therefore was eliminated from analysis. The data was first 
fitted for dissociation and a kd of 0.08±0.01s-1 was calculated. Considering the dissociation 
rate constant to be 0.08s-1, data was fitted for an association constant ka of 150M-1s-1 and a 
corresponding KD of 500µM was observed for most curves. The fitted data for association 
as well as dissociation is shown in the Figure 6.3-5.   
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Figure 6.3-5  Kinetic analysis of P-13 with sEGFR. Data was fitted using various concentrations of P-13 
(800, 600, 400, 300 and 200µM) injected at 30µl/min over sEGFR immobilized on the sensor surface. 
Kinetic rate constants were determined by fitting the data for dissociation (A) and association separately. 
Equilibrium dissociation constant was calculated from the obtained rate constants.  
  
6.4  Discussion 
        We have determined that the dissociation rate constant for EGF binding to sEGFR is 
0.04s-1 which is comparable to the rate constants shown in previous cell culture studies. 
Table 6.3-1 shows the equilibrium dissociation constant for EGF and sEGFR binding 
(A) 
(B) 
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assuming heterogeneous ligand parallel interactions model and is comparable with Iyer et 
al,. The affinity of sEGFR measured by Biacore is 100 fold lower than that in cells. This 
may be due to the fact that extra cellular domain of EGFR has much lower binding affinity 
than that of EGFR full length (Brown et al., 1994). Also, deglycosylation of the 
recombinant protein used might have further decreased the affinity suggesting that the KD 
values obtained using SPR studies may be 100 fold higher than measured in vitro.   
        There have been conflicting results on the binding stoichiometry of the EGF/EGFR 
interaction (Domagala et al., 1999). The binding stoichiometry using full length EGFR 
purified by affinity chromatography from A431 cells is reported to be 1:1; by Weber et al., 
1984 in their studies. The later studies in cells, demonstrated that EGF binds to EGFR with 
two distinct dissociation constants: a minority (2%–5%) of high-affinity (KD~0.1nM) 
receptors and a majority (95%–98%) of low-affinity (KD~10nM) receptors (Schlessinger et 
al., 1986, 88). In Biacore studies carried over by Domagala et al., they reported that global 
analysis of EGF/sEGFR binding curves indicated that a simple 1:1 interaction did not 
adequately describe the experimental data, and that more complex interactions were 
operative. Additionally, competition analysis of the data obtained using either direct 
measurement of free sEGFR using Biacore or Fluorescence Anisotropy experiments 
yielded biphasic Scatchard plots indicative of multiple binding sites, with 10-15% of the 
high affinity sites (Domagala et al., 2000). 
        In our studies, we immobilized sEGFR in order to closely imitate the natural system. 
The flexibility of the dextran matrix and high local concentrations of immobilized 
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receptors made it possible to form complexes that mimic the cell surface better than 
solution phase assays (Myszka et al., 1999). Nonetheless, the data fitting using 
simultaneous ka/kd model indicated a two state binding of EGF and sEGFR with a 90% low 
affinity site with KD of 115±10nM which is consistent with KD of EGF binding to sEGFR 
established in Li et al., and Iyer et al. The other 10% is high affinity binding and the 
physical reasons causing this are unclear.     
        Since Cetuximab is a bivalent monoclonal antibody, data fitting for C225 interaction 
with sEGFR was done using bivalent analyte model. The dissociation constant was shown 
in Table 6.3-2 in comparison with literature. We immobilized sEGFR on the surface and 
made C225 to flow on the ligand. When the surface density of sEGFR was 100RU, the 
data fitted well to 1:1 Langmuir model. As surface density of sEGFR was increased, fitting 
showed significant deviations. This may be due to the increased avidity effects on the 
surface. Avidity could be described as follows. If an antibody is in solution, it has the 
potential to cross-link with two antigens on the surface. This will result in an apparent 
higher affinity and the kinetics cannot be described with a simple interaction model 
(Myszka et al., 1999). Studies by Shiqing Li et al., showed that Cetuximab binds to 
sEGFR with a dissociation constant of 2.3nM which is 10 fold greater than what we got in 
our studies. This may be due to the difference in experimental methods adopted and the 
nature of the Cetuximab used. Li et al., used a monovalent Fab fragment in their study 
where as we used bivalent antibody. Also, in our studies, we reported the dissociation rate 
constant for immobilized sEGFR with Cetuximab, as an analyte, regeneration was possible 
in our system. This was practically not possible with sEGFR binding to immobilized Fab 
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as the sEGFR sticks very tightly to the Fab and never comes off under normal buffer 
conditions (Li et al., 2005).  
        P-13 interactions with sEGFR showed a binding with significantly lower affinity as 
compared to the prototypical ligands such as EGF. The KD of the peptide is reported to be 
500µM and the kinetic dissociation rate constant is 0.08±0.01s-1. Although the equilibrium 
dissociation constant is way too high for comparison, the dissociation rate constant seems 
to be comparable to a nano molar binder, Hydroxybenzylpindolol (Rimon et al., 1980). As 
the association rate constant is very low, the peptide is rendered as a very weak binder. 
This suggests that the binding region of the peptide on the receptor could be highly 
inaccessible. We may conclude from this study that target location plays an important role 
for peptide therapeutics. In our study, to get a more promising binder, the upper regions of 
domain III must be considered as target.    
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CHAPTER 7  Future Work 
 
 
• In order to obtain more reliable kinetic rate constants and equilibrium binding 
constant for the P-13-sEGFR interaction, it is necessary to repeat the Biacore 
experiments more number of times with higher concentrations of peptide. Due to 
the limited availability of resources, we had to optimize our experiments.  
 
• To obtain a wider knowledge on interaction of the peptide P-13 with the receptor 
and to determine if the peptide has any inhibiting effect on EGFR cell signaling, it 
is recommended to carry on cell studies with the peptide. 
 
• In order to explore the structure of high affinity binding of EGF and sEGFR, it is 
suggested to recover the EGF-sEGFR complex and carry forward x-ray 
crystallography studies on the complex. 
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